dextroamphetamine has been researched along with Weight Loss in 12 studies
Dextroamphetamine: The d-form of AMPHETAMINE. It is a central nervous system stimulant and a sympathomimetic. It has also been used in the treatment of narcolepsy and of attention deficit disorders and hyperactivity in children. Dextroamphetamine has multiple mechanisms of action including blocking uptake of adrenergics and dopamine, stimulating release of monamines, and inhibiting monoamine oxidase. It is also a drug of abuse and a psychotomimetic.
(S)-amphetamine : A 1-phenylpropan-2-amine that has S configuration.
Weight Loss: Decrease in existing BODY WEIGHT.
| Excerpt | Relevance | Reference |
|---|---|---|
| " This review addresses the following three topics: a brief discussion of older weight loss medications approved for short-term use (benzphetamine, phendimetrazine, diethylpropion, mazindol, and phentermine), as well as over-the-counter adrenergic drugs (phenylpropanolamine and ephedrine); recent clinical studies documenting the safety and efficacy of a new medication for obesity treatment, sibutramine, recently approved by the Food and Drug Administration for long-term use; and recent studies characterizing the valvulopathy associated with fenfluramine and dexfenfluramine, serotonergic medications for obesity which have been removed from the markets." | 8.80 | Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity. ( Ryan, DH, 2000) |
| "In a controlled study (the control group receiving pyribenzamine) it was observed that reserpine, in the dosage used, had no effect on weight loss in patients receiving d-amphetamine sulphate (Dexedrine(R)) and methyl cellulose (Cellothyl(R)) while on 1,000-calorie diets as compared with the control group." | 7.64 | Reserpine in weight reduction. The effect in obese patients on 1,000-calorie diets: a controlled study. ( SMITH, MC, 1959) |
| " This review addresses the following three topics: a brief discussion of older weight loss medications approved for short-term use (benzphetamine, phendimetrazine, diethylpropion, mazindol, and phentermine), as well as over-the-counter adrenergic drugs (phenylpropanolamine and ephedrine); recent clinical studies documenting the safety and efficacy of a new medication for obesity treatment, sibutramine, recently approved by the Food and Drug Administration for long-term use; and recent studies characterizing the valvulopathy associated with fenfluramine and dexfenfluramine, serotonergic medications for obesity which have been removed from the markets." | 4.80 | Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity. ( Ryan, DH, 2000) |
| "Dextroamphetamine sulfate was used for weight gain when no other etiologic factor was found." | 3.81 | The confounding effect of the development of idiopathic orthostatic edema and thyrotoxcosis on weight fluctuation related to effects on free water clearance in a woman with long-standing surgically induced panhypopituitarism and diabetes insipidus. ( Check, JH; Weidner, J, 2015) |
| "In a controlled study (the control group receiving pyribenzamine) it was observed that reserpine, in the dosage used, had no effect on weight loss in patients receiving d-amphetamine sulphate (Dexedrine(R)) and methyl cellulose (Cellothyl(R)) while on 1,000-calorie diets as compared with the control group." | 3.64 | Reserpine in weight reduction. The effect in obese patients on 1,000-calorie diets: a controlled study. ( SMITH, MC, 1959) |
| " Safety assessments included treatment-emergent adverse events (TEAEs), vital signs, and electrocardiograms." | 2.74 | Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study. ( Findling, RL; Gao, J; Ginsberg, LD; Jain, R, 2009) |
| " Most adverse events were mild to moderate and occurred during the first 4 weeks." | 2.73 | Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder. ( Childress, AC; Findling, RL; Krishnan, S; McGough, JJ, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (50.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 2 (16.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Check, JH | 2 |
| Weidner, J | 1 |
| Findling, RL | 2 |
| Childress, AC | 1 |
| Krishnan, S | 1 |
| McGough, JJ | 1 |
| Ginsberg, LD | 1 |
| Jain, R | 1 |
| Gao, J | 1 |
| Cohen, R | 1 |
| FAZEKAS, JF | 1 |
| EHRMANTRAUT, WR | 1 |
| CAMPBELL, KD | 1 |
| NEGRON, MC | 1 |
| SMITH, MC | 1 |
| GURTLER, J | 1 |
| GELVIN, EP | 1 |
| McGAVACK, TH | 1 |
| Schertz, M | 1 |
| Adesman, AR | 1 |
| Alfieri, NE | 1 |
| Bienkowski, RS | 1 |
| Ryan, DH | 1 |
| Jones, JR | 1 |
| Caul, WF | 1 |
| Ryan, LJ | 1 |
| Martone, ME | 1 |
| Linder, JC | 1 |
| Groves, PM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Open-Label, Multi-Center, Dose-Optimization Study Evaluating the Efficacy, Safety and Tolerability of Vyvanse (Lisdexamfetamine Dimesylate) 20-70mg in Children Aged 6-12 Diagnosed With ADHD[NCT00500071] | Phase 4 | 318 participants (Actual) | Interventional | 2007-06-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Expression and Emotional Scale for Children (EESC) consists of 29 items rated on a scale from 1 (not true at all) to 5 (very much true). Lower scores reflect better emotional outcomes. (NCT00500071)
Timeframe: Baseline and 7 weeks
| Intervention | Units on a scale (Mean) |
|---|---|
| Vyvanse | -7.4 |
Change in the Attention Deficit Hyperactivity Disorder Rating Scale-fourth edition (ADHD-RS-IV) total score from baseline. The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. (NCT00500071)
Timeframe: Baseline and 7 weeks
| Intervention | Units on a scale (Mean) |
|---|---|
| Vyvanse | -28.6 |
Clinical Global Impression-Improvement (CGI-I) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 or 2 on the scale. (NCT00500071)
Timeframe: 7 weeks
| Intervention | Participants (Number) |
|---|---|
| Vyvanse | 284 |
Parent Global Assessment (PGA) consists of a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). Improvement is defined as a score of 1 (very much improved) or 2 (much improved) on the scale. (NCT00500071)
Timeframe: 7 weeks
| Intervention | Participants (Number) |
|---|---|
| Vyvanse | 267 |
Behavior Rating Inventory of Executive Function (BRIEF) is an 86-item questionnaire composed of three scales (Global Executive Composite, Behavioral Recognition Index, and Metacognition Index). Items are rated 1 (never), 2 (sometimes), and 3 (often). Lower scores reflect better functioning. (NCT00500071)
Timeframe: Baseline and 7 weeks
| Intervention | Units on a scale (Mean) | ||
|---|---|---|---|
| Global Executive Composite | Behavioral Recognition Index | Metacognition Index | |
| Vyvanse | -17.9 | -15.4 | -17.6 |
Change in the Attention Deficit Hyperactivity Disorder Rating Scale-fourth edition (ADHD-RS-IV) total score from baseline. The ADHD-RS-IV consists of 18 items scored on a 4-point scale ranging from 0 (no symptoms) to 3 (severe symptoms) with total score ranging from 0 to 54. (NCT00500071)
Timeframe: Baseline and 1, 2, 3, 4, 5, 6, and 7 weeks
| Intervention | Units on a scale (Mean) | ||||||
|---|---|---|---|---|---|---|---|
| Week 1 | Week 2 | Week 3 | Week 4 | Week 5 | Week 6 | Week 7 | |
| Vyvanse | -11.3 | -17.8 | -21.7 | -25.4 | -27.0 | -28.9 | -29.8 |
1 review available for dextroamphetamine and Weight Loss
| Article | Year |
|---|---|
Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity.
Topics: Adrenergic Agents; Appetite Depressants; Cyclobutanes; Dexfenfluramine; Dextroamphetamine; Fenfluram | 2000 |
2 trials available for dextroamphetamine and Weight Loss
| Article | Year |
|---|---|
Long-term effectiveness and safety of lisdexamfetamine dimesylate in school-aged children with attention-deficit/hyperactivity disorder.
Topics: Administration, Oral; Appetite; Attention Deficit Disorder with Hyperactivity; Child; Dextroamphetam | 2008 |
Effectiveness, safety, and tolerability of lisdexamfetamine dimesylate in children with attention-deficit/hyperactivity disorder: an open-label, dose-optimization study.
Topics: Appetite; Attention Deficit Disorder with Hyperactivity; Central Nervous System Stimulants; Child; D | 2009 |
9 other studies available for dextroamphetamine and Weight Loss
| Article | Year |
|---|---|
The confounding effect of the development of idiopathic orthostatic edema and thyrotoxcosis on weight fluctuation related to effects on free water clearance in a woman with long-standing surgically induced panhypopituitarism and diabetes insipidus.
Topics: Antidiuretic Agents; Antithyroid Agents; Deamino Arginine Vasopressin; Dextroamphetamine; Diabetes I | 2015 |
Successful treatment of a female with chronic pseudo-intestinal obstruction with sympathomimetic amines and thyroid hormone replacement.
Topics: Dextroamphetamine; Female; Humans; Intestinal Pseudo-Obstruction; Sympathomimetics; Thyroxine; Weigh | 2010 |
Comparative effectiveness of phenylpropanolamine and dextro amphetamine on weight reduction.
Topics: Amphetamine; Amphetamines; Dextroamphetamine; Humans; Obesity; Phenylpropanolamine; Sympathomimetics | 1959 |
Reserpine in weight reduction. The effect in obese patients on 1,000-calorie diets: a controlled study.
Topics: Dextroamphetamine; Diet, Reducing; Humans; Obesity; Reserpine; Weight Loss | 1959 |
[Medically indicated weight reduction with "Dexten" and "Barbidex" (Nicholas)].
Topics: Dextroamphetamine; Humans; Obesity; Phenobarbital; Weight Loss | 1963 |
Dexedrine and weight reduction.
Topics: Dextroamphetamine; Humans; Obesity; Weight Loss | 1949 |
Predictors of weight loss in children with attention deficit hyperactivity disorder treated with stimulant medication.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Body Height; Body Mass Index; Central Ner | 1996 |
Time course of the effect of amphetamine on eating is biphasic.
Topics: Animals; Appetite; Conditioning, Classical; Dextroamphetamine; Dose-Response Relationship, Drug; Dru | 1989 |
Cocaine, in contrast to D-amphetamine, does not cause axonal terminal degeneration in neostriatum and agranular frontal cortex of Long-Evans rats.
Topics: Animals; Axons; Behavior, Animal; Cerebral Cortex; Cocaine; Corpus Striatum; Dextroamphetamine; Dopa | 1988 |